Articles and Videos
Tribe Webinar: Exploring the Neuroprotective Qualities of Rare Cannabinoids
InMed's President and CEO, Eric A. Adams, and Senior VP, Preclinical Research and Development, Dr. Eric Hsu, talks about "Exploring the Neuroprotective Qualities of Rare...
Source: Tribe Public
Epidermolysis Bullosa News: INM-755 Found Safe in 5 Adults With EB, Trial Opens to Adolescents
Epidermolysis Bullosa News writes about InMed's Phase 2 clinical trial of INM-755 cannabinol cream, an investigational new treatment for epidermolysis bullosa. Excerpt: INM-755 was found to...
The Dales Report – InMed Pharmaceuticals Unveils Industry Leading Portfolio
Jerry P. Griffin, VP of Sales and Marketing at BayMedica, InMed's subsidiary, is interviewed by Shadd Dales of the The Dales Report to talk about...
Source: The Dales Report
Pharma Tech Outlook: InMed Introduces THCV Into the Health and Wellness Industry
InMed's THCV will bring ample opportunity to the health sector to scale up in the market. Read full story via Pharma Tech Outlook.
What are cannabinoid analogs?
Cannabinoid analogs are novel cannabinoid compounds that are slightly modified from the naturally occurring cannabinoids in the plant. Since they have a new molecular structure...
The Intersection Between Medical and Health & Wellness: Force For Knowledge Cannabis Symposium Panel Discussion
InMed Pharmaceuticals' Dr. Shane Johnson and Radicle Science’s Dr. Jeff Chen join the Force Family Office's Force For Knowledge Cannabis Symposium: The Intersection Between Medical...
Source: Force Family Office
